Pharmacokinetic observations on dapsone in dermatitis herpetiformis.
The pharmacokinetics of dapsone (DDS) and monoacetyldapsone (MADDS) following an oral dose of 150 mg DDS were studied in sixteen patients with dermatitis herpetiformis and seven normal subjects. No differences in DDS disposition were observed between the two groups. The maintenance dose of DDS for individual patients was not significantly correlated with jejunal biopsy morphology, DDS or MADDS half-lives, or the area under the plasma concentration-time curves for DDS or MADDS. DDS plasma protein binding was normal in patients and did not apparently determine the concentration of DDS in skin biopsies, for which the skin/plasma DDS concentration ratio was approximately unity. There was no undue representation of acetylator phenotype in the patient group and no correlation between maintenance dose and MADDS/DDS ratio was noted. The determinants of the maintenance DDS dose have not been found. This may relate to pharmacodynamic differences, but alternatively the concentration of oxidative metabolites rather than DDS or MADDS could be responsible for the therapeutic activity in dermatitis herpetiformis.
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000097:blood; D003622:Dapsone / Q000031:analogs & derivatives / Q000097:blood*; D003874:Dermatitis Herpetiformis / Q000097:blood* / Q000473:pathology; D006207:Half-Life; D006801:Humans; D007421:Intestine, Small / Q000473:pathology; D007700:Kinetics; D008875:Middle Aged; D011485:Protein Binding; D012867:Skin / Q000473:pathology
D000890:Anti-Infective Agents; D003622:Dapsone; C018965:monoacetyldapsone